Cefotetan-induced immune hemolytic anemia following prophylaxis for cesarean delivery

Sherry Shariatmadar, Jill R. Storry, Laima Sausais, Marion E. Reid

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Second- and third-generation cephalosporins, notably cefotetan, are increasingly implicated in severe, sometimes fatal immune-mediated hemolytic anemia. We describe a 26-year-old woman who developed severe hemolytic anemia 2 weeks after receiving a single prophylactic dose of cefotetan during cesarean delivery. The patient's DAT was weakly reactive for IgG and her serum reacted with cefotetan-coated RBCs. The antibody had a titer of 4096 by antiglobulin testing. The patient required treatment with two units of PRBCs and experienced gradual resolution of hemolysis. Our case emphasizes the need for increased awareness of delayed onset hemolytic anemia following prophylactic use of cefotetan.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
Issue number1
StatePublished - 2004
Externally publishedYes


  • Cefotetan
  • Cesarean delivery
  • DAT
  • Drug-induced hemolytic anemia
  • Immune hemolytic anemia

ASJC Scopus subject areas

  • Immunology
  • Hematology


Dive into the research topics of 'Cefotetan-induced immune hemolytic anemia following prophylaxis for cesarean delivery'. Together they form a unique fingerprint.

Cite this